Cell Processing revenue of $23.0 million , up 28% over Q2 2024

GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65%

GAAP net loss of $15.8 million , inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue

Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million , and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million

Conference call begins at 4:30 p.m. Eastern time today

BOTHELL, Wash. , Aug. 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results f

See Full Page